Heat Biologics Inc (NASDAQ:HTBX) rose 6.3% during trading on Friday . The company traded as high as $0.68 and last traded at $0.67, approximately 203,525 shares were traded during trading. A decline of 57% from the average daily volume of 475,588 shares. The stock had previously closed at $0.63.
HTBX has been the topic of a number of analyst reports. Alliance Global Partners set a $6.00 price objective on Heat Biologics and gave the company a “buy” rating in a report on Friday, May 17th. ValuEngine raised VESTAS WIND SYS/ADR from a “hold” rating to a “buy” rating in a report on Thursday, May 9th.
The company has a current ratio of 5.70, a quick ratio of 5.70 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $22.86 million, a price-to-earnings ratio of -0.75 and a beta of 1.95. The company’s fifty day moving average price is $0.73.
Heat Biologics (NASDAQ:HTBX) last issued its quarterly earnings data on Wednesday, May 15th. The biopharmaceutical company reported ($0.17) EPS for the quarter. The company had revenue of $0.70 million for the quarter. Heat Biologics had a negative net margin of 319.80% and a negative return on equity of 68.17%. On average, analysts forecast that Heat Biologics Inc will post -0.57 earnings per share for the current fiscal year.
A hedge fund recently bought a new stake in Heat Biologics stock. CVI Holdings LLC acquired a new stake in shares of Heat Biologics Inc (NASDAQ:HTBX) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 1,557,768 shares of the biopharmaceutical company’s stock, valued at approximately $1,527,000. Heat Biologics comprises about 3.4% of CVI Holdings LLC’s portfolio, making the stock its 6th largest position. CVI Holdings LLC owned 6.70% of Heat Biologics as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 5.94% of the company’s stock.
About Heat Biologics (NASDAQ:HTBX)
Heat Biologics, Inc, a biopharmaceutical company, focuses on developing approaches to activate and co-stimulate a patient's immune system against cancer in the United States. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors hot and be administered in combination with checkpoint inhibitors and other immuno-modulators to enhance clinical effectiveness.
Featured Article: What is the downside to momentum investing?
Receive News & Ratings for Heat Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heat Biologics and related companies with MarketBeat.com's FREE daily email newsletter.